AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03735472 — intervention group
Intervention type: DEVICE
Intervention: Thoraflex™ Hybrid
Description: The Thoraflex™ Hybrid device is particularly suited to the treatment of extended lesions of the ascending aorta, the aortic arch and the descending aorta, which constitute a major challenge in cardiovascular surgery.~It enables, during a single surgical operation, combination of the Frozen Elephant Trunk technique and a 4-branch prosthesis of the aortic arch, thus enhancing the arsenal of the surgeon in the treatment of complex diseases of the aortic arch.
Study NCT00346853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole
Description: 15 mg/kg dose
Study NCT00346853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT04217772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography Angiography
Description: A device testing the vascular density in the retina
Study NCT01539577 — intervention group
Intervention type: DRUG
Intervention: dexamethasone 700 μg intravitreal implant
Description: dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
Study NCT00947947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Information Program for Safer Sex
Description: Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
Study NCT00947947 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Tailored Information Program for Safer Sex
Description: Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
Study NCT04262206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
Study NCT04262206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
Study NCT04168281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: instead of PCI patients will be followed-up with MRI
Study NCT03387761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: For Cohort 1:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~* Day 1: Ipilimumab 1 mg/kg~* Days 22: Ipilimumab 1 mg/kg
Study NCT03387761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For Cohort 1:~* Day 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~* Days 1 and 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg
Study NCT04201587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Henna application
Description: Henna application was performed to the patients in the intervention group. The patient was instructed to apply henna before going to bed at night, and after waking up in the morning (for an average of 8-10 hours) was instructed to wash with only water. The patient was asked to do this application at home after the second and third chemotherapy cycles. Thus, the patient applied henna twice in total (fifteen days apart).
Study NCT05716568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast dose reduction, CT-angiography
Description: Contrast dose reduction for CT-angiography in pre-operative aorta
Study NCT03564353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS
Study NCT01760798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Study NCT01760798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Study NCT02033278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of autologous mononuclear bone marrow cells
Description: Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
Study NCT02033278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Placebo infusion plus conventional medical treatment (as indicated by clinician)
Study NCT00467207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Study NCT00467207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Study NCT00467207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Study NCT01397149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form, frequency and duration exactly as experimental arm.
Study NCT01397149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Phase I:~Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to > 400,000/µl).~Phase II:~Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I.
Study NCT02786004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Field Digital Mammography
Study NCT02786004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis
Study NCT02990871 — intervention group
Intervention type: OTHER
Intervention: early neurological rehabilitation
Description: start of neurological rehabilitation between 3rd and 15th day after ABI
Study NCT02990871 — intervention group
Intervention type: OTHER
Intervention: no-early neurological rehabilitation
Description: start of neurological rehabilitation between 20th and 90th day after ABI
Study NCT03294200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriCinch Coil System implantation
Description: Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
Study NCT02502747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhu G-CSF
Description: rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
Study NCT02502747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimal standard of care
Description: Optimal standard of care
Study NCT02502747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myocardial Contrast Echocardiography
Description: Myocardial Contrast Echocardiography with sulphur hexafluoride.
Study NCT02502747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial Contrast Echocardiography
Description: Myocardial Contrast Echocardiography with sulphur hexafluoride.
Study NCT02373631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling, Conventional PT
Description: Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
Study NCT02373631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
Study NCT04516005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: foot reflexology
Description: Acupressure was applied at the plantar side of the right foot at the first metatarsal bone, around 1-1.5 centimeters proximal to the first metatarsophalangeal joint. (Figure 2) Approximately 3-kilogram pressure was applied by using a knuckle of the right index finger (dorsal part of the proximal interphalangeal joint in flexing position) in a perpendicular manner and held for 15 seconds (sec) then released for 5 sec. This hold-release cycle was done 5 times over the course of 2 min. This method was recommended by the Department of Thai Traditional and Alternative Medicine in accordance with the Zone theory and the Meridian theory.
Study NCT03297502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimecrolimus cream 1%
Study NCT03297502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel (pimecrolimus) cream 1%
Study NCT03297502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02082470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow-up care
Description: Undergo survivorship care planning
Study NCT02082470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active surveillance
Description: Undergo cancer surveillance
Study NCT02082470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02082470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02434159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart scan
Study NCT01979601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial
Study NCT02336451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.
Study NCT03758547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: in-exufflator technique
Description: application through a device of 10 cycles using positive pressure (30 cmH20) during inspiration and negative pressure (-30 cmH20) during exhalation
Study NCT03758547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percussion technique
Description: sliding venturi system (phasitron), powered by compressed gas that can be changed from 0.8 up to 3.5 bar and that generates the oscillations in the range of 80-650 cycles/min
Study NCT04700683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noctrix Health NPNS device v1.0 - Active
Description: Wearable device programmed to deliver electrical stimulation to peripheral nerves of the lower limbs.
Study NCT04700683 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Noctrix Health NPNS device v1.0 - Sham
Description: Wearable device programmed to deliver sham stimulation.
Study NCT01558817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed Assent
Description: Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
Study NCT01558817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Brochure
Description: An informational brochure about CPR will be given without a discussion with a physician.
Study NCT00759122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine (Effexor)
Description: Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
Study NCT00759122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
Study NCT00746629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS
Description: Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit.
Study NCT00746629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS
Description: Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit.
Study NCT01593930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine(IANB)
Description: Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
Study NCT01593930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 Articaine(Infiltration)
Description: Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
Study NCT01979601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04160637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immediate postoperative PTH serum sampling and cut-off value identification
Description: The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.
Study NCT03700918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DaVingiTR System
Description: DaVingiTR Tricuspid valve annuloplasty repair device
Study NCT03332095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine (DOR)
Description: 100 mg of DOR administered orally
Study NCT03332095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)
Description: DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg) once daily
Study NCT03332095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral (ARV) medications
Description: Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
Study NCT01637883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzydamine HCl
Description: 3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
Study NCT01179932 — intervention group
Intervention type: OTHER
Intervention: No Intervention Used
Description: Our study is observational; therefore, there is no type of intervention being used.
Study NCT02431104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser
Description: Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
Study NCT01593930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 Articaine(Infiltration)
Description: Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
Study NCT01593930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine(IANB)+1Articaine(Infiltration)
Description: Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
Study NCT01181245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: 3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
Study NCT02069197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic diet
Description: ketogenic diet will consist of 3:1\[fat\]:\[protein+carbohydrate\]weight ratio with 1600 kcal restriction. Diet will last 9 months.
Study NCT02069197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.
Study NCT02069197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized diet
Description: Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
Study NCT04415827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bicycle ergometry test with spiroergometry
Description: The 1st testing will be carried out on the 28-31th day of the disease, which corresponds to the period of the expected normalization of temperature, improvement of well-being, positive dynamics of radiological (with community-acquired pneumonia) and laboratory data, the 2nd test - after 3 months, the 3rd - after 6 months and IV - after 12 months.~Load testing will be carried out on a bicycle ergometer with an initial power of 25 watts with a further increase of 25 watts every 3 minutes. The cessation of the load will be carried out upon the appearance of signs set forth in the recommendations of the World Health Organization Expert Committee (1970)
Study NCT04330690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: 2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care
Study NCT04330690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 400 mg enterally daily for 14 days plus standard of care
Study NCT04330690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/kg IV given one time, over 2 hours plus standard of care
Study NCT04330690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10
Study NCT04330690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT Peptide
Description: 5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
Study NCT00307047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study NCT00307047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study NCT00379769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone maximum 8 mg per day
Study NCT00379769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Sulfonylurea (SU) maximum permitted daily dose
Study NCT00379769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea (SU) maximum permitted daily dose
Study NCT00379769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin maximum permitted daily dose .
Study NCT00379769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin maximum permitted daily dose .
Study NCT02711319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes